Research
Hormonal
Certain metabolic and comorbid conditions disproportionately affect women.
Practitioners should consider gender-specific factors in obesity management.
StrongSupportsmedium confidence
Certain metabolic and comorbid conditions disproportionately affect women.
Why this rating
The review discusses relevant updates and issues specific to women.
Source
Medical Management of Obesity
Eduardo Grunvald · Clinical Obstetrics & Gynecology · 2014
DOI 10.1097/grf.0000000000000041
reviewCited 19×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →